Galcanezumab reduces migraine frequency in phase 2

  • Goadsby PJ & al.
  • J Neurol Neurosurg Psychiatry
  • 19 Apr 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients who received galcanezumab for the prevention of migraine had a significantly higher response rate and a bigger reduction in migraine headache days (MHD) than those receiving placebo.

Why this matters

  • The majority of patients reported onset of efficacy within the first week of galcanezumab treatment, with a sustained response throughout the 3-month treatment period.

Study design

  • Post hoc analysis of a randomized, double-blind phase 2a study.
  • 217 patients with migraine received galcanezumab injection every 2 weeks (n=107) or placebo (n=110) for 12 weeks.
  • Funding: Eli Lilly and Company.

Key results

  • Significantly higher response rate in galcanezumab group at week 1 compared with placebo (62% vs 42%; P<.05>
  • Significant decrease in weekly MHD with galcanezumab at week 1 compared with placebo (−0.89 vs −0.53; P=.018) that remained significant, except in weeks 6 and 9 (P<.05>
  • 47% of patients responding to galcanezumab within 1 month maintained that response through months 2 and 3 (vs placebo, 25%).
  • Among galcanezumab nonresponders at month 1, 27% responded at months 2 and 3 (vs placebo, 20%).
  • Among galcanezumab nonresponders in months 1 and 2, 50% responded at month 3 (vs placebo, 24%).  

Limitations

  • Original study not designed to measure weekly efficacy outcomes.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit